Publications and Presentations

From 2015-2021, the PIVOT pediatric preclinical testing consortium was called the NCI Pediatric Preclinical Testing Consortium (PPTC).

Publications

Publications: 2016-2025 (PubMed)

Presentations

2026

American Association of Cancer Research (AACR) Annual Meeting

Preclinical evaluation of a dnTGFβR-armored GPC3 CAR-T (AZD5851) in pediatric solid tumor PDX models – A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT) (abstract) (poster pdf)

AZD5851, a TGF-β-resistant GPC3 CAR-T cell product, prolongs animal survival times in patient derived orthotopic xenograft models of medulloblastoma and atypical teratoid rhabdoid tumor (abstract) (poster pdf)

Efficacy of ABBV-706, a SEZ6-targeted topoisomerase 1 inhibitor ADC: A report from the Pediatric Preclinical In Vivo Testing (PIVOT) Program (abstract) (poster pdf)

The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of pediatric medulloblastoma patient-derived orthotopic xenograft mouse models (abstract) (poster pdf)

Targeting MYB with REM-422 for the treatment of pediatric T-cell acute lymphoblastic leukemia – A report from the Pediatric Preclinical Testing Consortium (PIVOT) (abstract )

2025

American Association of Cancer Research (AACR) Annual Meeting

The CLK/DYRK inhibitor SM09419 shows potent efficacy across a broad panel of pediatric preclinical xenograft models: A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT) (pdf)

Preclinical evaluation of the AKR1C3-activated alylator, OBI-3424, in hepatoblastoma- A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT) (pdf)

The B7-H3 targeting antibody-drug conjugate (ADC) Vobramitamab Duocarmazine (Vobra Duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) consortium (pdf)

2024

American Association of Cancer Research (AACR) Annual Meeting

The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia (pdf)

In vivo efficacy of anti-B7-H3 (CD276) antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): an update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program (pdf)

An evaluation of patritumab deruxtecan (HER3-DXD, U31402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma- A report from the NCI PIVOT Program (pdf)

Pediatric Preclinical In Vivo Testing (PIVOT) data portal enables access to 15 years of treatment study data in support of prospective study design (pdf)

2023

Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC)
The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLLr acute lymphoblastic leukemia (pdf)

Connective Tissue Oncology Society (CTOS)

Preclinical evaluation of AMG 650, A small molecule inhibitor of KIF18A, in pediatric solid tumors by the Pediatric Preclinical In Vivo testing (PIVOT) program (pdf)

2022

American Association of Cancer Research (AACR) Annual Meeting

Evaluation of the in vivo efficacy of the B7-H3 antibody-drug conjugate (ADC) DS-7300a: A report from the Pediatric Preclinical In Vivo Testing (PIVOT) program (pdf)

2021

American Society of Clinical Oncologists (ASCO) Annual Meeting

Testing of B7-H3 Targeting Antibody-Drug Conjugate (ADC) MGC018 in Models of Pediatric Solid Tumors by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

2020

American Association of Cancer Research (AACR) Annual Meeting

Evaluation of ROR1-targeted Antibody-Drug Conjugates (ADCs) Against ROR1 Expressing Pediatric Preclinical Models — A Report from the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

Pediatric Preclinical Testing Consortium Evaluation of the Dual SYK/FLT3 Inhibitor TAK-659 in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia (pdf)

Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium osteosarcoma in vivo models (pdf)

The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL) (pdf)

Integrative surfaceome profiling identifies immunotherapeutic targets in osteosarcoma and preclinical testing of BT1769, an MT1-MMP-targeted Bicycle® toxin conjugate, in osteosarcoma by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)

American Association for Cancer Research-National Cancer Institute- European Organization for Resesarch and Treatment of Cancer Annual Meeting (AACR NCI EORTC)

Pediatric Preclinical Testing Consortium evaluation of the XPO1 inhibitor eltanexor against xenograft models of pediatric acute lymphoblastic leukemia (pdf)

Preclinical Evaluation of Trastuzumab Deruxtecan (T-DXd; DS-8201a), a HER2 Antibody Drug Conjugate, in Pediatric Solid Tumors by the Pediatric Preclinical Testing Consortium (PPTC) (pdf)